Jeff Ryel

Last week, the FDA issued draft guidance on conducting multiregional clinical trials (MRCTs) for oncology. You can review these potential new regulatory expectations below if you're involved in oncology trials. https://lnkd.in/ed8a6vdH #OncologyTrials #ClinicalTrials #FDA #MRCT #DrugDevelopment

8

Congrats to Lytix Biopharma and Verrica Pharmaceuticals on the phenomenal preliminary #ph2 data of VP-315. Great news for #basalcellcarcinoma patients. All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to continue to grow due to aging US population, better diagnosis and increased exposure to risk factors. Innovation Norway / Innovation Norway Americas

2

Maximizing the Role of MSLs in Your Product Launch When it comes to launching a new pharmaceutical or biotech product, how is your organization utilizing Medical Science Liaisons? Are you deploying them early enough in the commercialization process to make a real impact? MSLs can play a critical role in ensuring that a product not only enters the market successfully but thrives long after its launch. Engaging KOLs Early 🔑 One of the key strengths of MSLs is their ability to build relationships with Key Opinion Leaders well before the product reaches the market. These early interactions provide valuable insights that shape clinical development and commercial strategies. Engaging MSLs early ensures that KOLs are well-informed and ready to support your product’s introduction. Translating Science into Action 🧬 MSLs serve as the bridge between complex clinical data and real-world practice. They play a pivotal role in helping HCPs understand the clinical and scientific benefits of your product. This ensures smoother adoption, as MSLs can effectively convey how a new therapy fits into current treatment paradigms or even how the new product may set a new standard of care. Creating a Strategic Feedback Loop 🔄 MSLs aren’t just educators—they’re listeners too. They gather crucial feedback from KOLs and frontline HCPs that can directly inform your commercial strategy. This feedback helps identify potential barriers to adoption, refine your messaging, and adjust tactics in real-time based on what’s happening in the market. Long-Term Support for Sustainability 📅 The value of MSLs extends well beyond the launch date. Post-launch, they continue to support HCPs with new clinical data, address ongoing questions, and reinforce the product’s value in the marketplace. This continuous engagement ensures long-term success and helps solidify your product’s position in the market. MSLs are a strategic asset in any successful product launch, from building early KOL relationships to supporting long-term clinical adoption. If your organization isn’t fully tapping into their potential, you may be missing out on key opportunities for launch success and sustained market growth. How is your organization integrating MSLs into your launch plan to maximize success? #MSLs #pharmalaunch #koldevelopment

20

16 Comments

Association of Northern California Oncologists (ANCO)’s ASCO24 highlights panel discussion with Eric Small American Society of Clinical Oncology (ASCO) #ANCO #ASCO #ASCO24 #Cancer #OncoDaily #Oncology

19

The annual meeting of the American Society of Clinical Oncology (ASCO) ended this week. Members of our team were there. Here's brief summary of the key themes that stood out from the meeting >> https://lnkd.in/ePVjs2ZH Authors: Mary Lee, Shankar Sundar, & Tahel Noy #oncology #cancerresearch #biotech #pharmaceuticals #ASCO2024 #ASCO24

42